指南与共识骨质疏松与代谢性骨病骨肿瘤

乳腺癌幸存者的激素治疗与骨质疏松:风险评估及对筛查建议的依从性

Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
指南 / 共识 · Osteoporos Int · 2018-11-09

该病例-队列研究基于1692例乳腺癌幸存者,发现芳香化酶抑制剂(AI)治疗显著增加骨质疏松风险,他莫昔芬后序贯AI治疗的HR为3.14,AI一线单药治疗的HR为5.53,该效应在停药随访期未持续。AI治疗的绝经后女性对骨密度筛查建议的依从性欠佳。

要点

  • AI一线单药治疗与骨质疏松风险升高相关(HR 5.53)。
  • 他莫昔芬后序贯AI治疗也与骨质疏松风险升高相关(HR 3.14)。
  • AI治疗的绝经后女性对筛查建议依从性欠佳。

核心结论

  • 乳腺癌active AI治疗加剧了年龄相关的骨密度自然下降。
  • 未来研究应聚焦筛查依从性的障碍/促进因素及有效策略以使实践符合共识标准。

研究设计与样本

  • 病例-队列研究,从「Leumit」医疗基金招募1692例2002年至2012年间诊断的原发性非转移性浸润性乳腺癌女性幸存者。
  • 基线随机抽取20%亚队列,并识别所有骨质疏松病例,采用加权Cox比例风险模型估计调整风险比(HR)及95%置信区间(CI)。

主要发现

  • 1692例乳腺癌幸存者中,中位随访5年期间312例发生骨质疏松。
  • 考虑死亡为竞争风险的粗累积骨质疏松发生率为25.7%(95% CI,21.9-29.5%)。
  • 多变量分析中,骨质疏松与他莫昔芬后序贯AI治疗正相关(HR,3.14;95% CI,1.44-6.88;P = .004)。
  • AI作为一线单药治疗时关联更明显(HR,5.53;95% CI,1.46-20.88;P = .012)。
  • 该效应在停药随访期未持续。

关键数值与推荐

  • 他莫昔芬后序贯AI治疗与骨质疏松风险的调整HR为3.14(95% CI,1.44-6.88;P = .004)。
  • AI一线单药治疗与骨质疏松风险的调整HR为5.53(95% CI,1.46-20.88;P = .012)。
  • 考虑死亡为竞争风险的粗累积骨质疏松发生率为25.7%(95% CI,21.9-29.5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The long-term impact of hormone therapy for breast cancer on risk of osteoporosis and the extent to which bone screening recommendations are implemented in daily practice remain unknown. We found that the aromatase inhibitor-induced risk of osteoporosis did not continue in the off-treatment follow-up. Adherence to screening recommendations was suboptimal. INTRODUCTION: A case-cohort study was undertaken to better understand the impact of hormone therapy on breast cancer patients' risk of osteoporosis, and to estimate the extent to which current bone mineral density screening recommendations are implemented in real-life daily practice. METHODS: This study is based on 1692 female breast cancer survivors recruited from "Leumit" healthcare fund, who were diagnosed with primary nonmetastatic invasive breast cancer between 2002 and 2012. A 20% random subcohort was sampled at baseline, and all osteoporosis cases were identified. Adjusted hazard ratios (HR) with 95% confidence intervals (CI) were estimated by weighted Cox proportional hazards models. RESULTS: Of 1692 breast cancer survivors, 312 developed osteoporosis during a median follow-up of 5 years. The crude cumulative incidence of osteoporosis accounting for death as a competing risk was 25.7% (95% CI, 21.9-29.5%). In multivariable analyses, osteoporosis was positively associated with the aromatase inhibitor (AI) sequential treatment after tamoxifen (HR, 3.14; 95% CI, 1.44-6.88; P = .004) but was more pronounced with AI use as upfront monotherapy (HR, 5.53; 95% CI, 1.46-20.88; P = .012). This effect did not continue in the off-treatment follow-up. In subgroup analysis by menopausal status, tamoxifen did not seem to confer a protective effect on bone health in postmenopausal patients. Adherence to screening recommendations in AI-treated postmenopausal women was suboptimal, particularly at baseline and after 48 months of continuous AI use. CONCLUSIONS: The natural, age-related reduction in bone density is exacerbated by breast cancer active AI treatment. Future research should focus on investigating screening adherence-related barriers/facilitators and effective strategies to bring practice in line with agreed standards.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Hamood R, Hamood H, Merhasin I, et al. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations. Osteoporos Int. 2018. PMID: 30413856. doi:10.1007/s00198-018-4758-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。